Alwin Capital
VC Fund
Beijing, China
Alwin Capital is a venture capital that specializes in early-stage life science investments.Driven by theme-focused research in life science, Alwin Capital has developed investment strategies that capture outstanding opportunities for innovative diagnostic and therapeutic developments. We are committed to the long-term investment in life sciencewith the pursuit of the excess investment return based on scientific insights.Founded in 2015, Alwin Capital was formed by former CICC senior executives, bringing in decades of experience in healthcare research and medical markets. Alwin Capital currently manages three venture funds with more than RMB 1 Billion in AUM, has invested in dozens of companies in life science, and cultivated a bunch of leading companies in respective segments.
- Total investments:
- 23
- Last investment:
- Lead investor:
- 26%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Alwin Capital invests in
Stages Alwin Capital invests in
Countries Alwin Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Lin Sibo
|
|||
4 more contacts available
Investment Focus
Industry
- Medical 8 (35%)
- Biotechnology 8 (35%)
- Health Care 7 (30%)
- Medical Device 4 (17%)
- Biopharma 3 (13%)
Stage
- Series A 7 (30%)
- Series B 7 (30%)
- Seed 2 (9%)
- Series C 1 (4%)
- Venture - Series Unknown 1 (4%)
Country
- China 14 (61%)
- United States 2 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Lin Sibo
Executive Director
|
Executive Director | Total investments: 4 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Sonosemi Medical
|
Sonosemi Medical is a provider of medical devices that specializes in the development of pan-vascular active interventional products, diagnosis, and treatment solutions. | Series B / Jul 08, 2026 | |
Puliyan
|
Puliyan is committed to becoming a leading industrial company in the medical industry, focusing on the fields of medical polymer materials and biological tissue engineering. | $50M / Series C / Jul 31, 2025 | |
Cosminde
|
Cosminde is a developer of gastroenterology soft electronic endoscope products. | Series A / Jul 08, 2025 | |
Bio-Link
|
Bio-Link is a drug development company that offers solutions for the life science industry. Bio-Link was founded in 2001 and was headquartered in Shanghai, China. | Venture - Series Unknown / Nov 11, 2024 | |
Sigma Squares Tech
|
Sigma Squares Tech is an automated manufacturing system developer. | Series B / Oct 17, 2024 | |
ICE Bioscience
|
ICE Bioscience was founded in 2010, an Innovative CRO+ Explorer company focusing in early drug discovery services from target validation to pre-clinical candidate identification, with strong capabilities and technologies in Immunology and Oncology, Cardiovascular and CNS diseases areas. ICE Bioscience provides high professional communication andflexible collaboration models, to speed up drug discovery process better and faster.ICE Bioscience has wide target-based panel screening platform ready-to-use, we keep trying to expand diverse techniques related to Biology and Pharmacology, to support various drug discovery purpose for different indications and clinical needs, we do have quite a lot of new assays development experience and passion, to accomplish target identification and assay validation, compounds screening from hit to lead, to pre-clinical drug candidate selection. | Series B / May 14, 2024 | |
|
Sanegene Bio
|
Sanegene Bio is currently operating in stealth mode. | $80M / Series A / Dec 01, 2023 | |
Immupeutics Medicine
|
Immupeutics Medical Technology Co., Ltd. is a biomedical research technology company dedicated to the development and application of tumor immunotherapy technology. The company mainly involves the research and application of immunotherapy for many different types of tumors. | Seed / Nov 14, 2023 | |
|
Sonosemi Medical
|
Sonosemi Medical is a provider of medical devices that specializes in the development of pan-vascular active interventional products, diagnosis, and treatment solutions. | $27.3M / Series B / Oct 26, 2023 | |
|
ICE Bioscience
|
ICE Bioscience was founded in 2010, an Innovative CRO+ Explorer company focusing in early drug discovery services from target validation to pre-clinical candidate identification, with strong capabilities and technologies in Immunology and Oncology, Cardiovascular and CNS diseases areas. ICE Bioscience provides high professional communication andflexible collaboration models, to speed up drug discovery process better and faster.ICE Bioscience has wide target-based panel screening platform ready-to-use, we keep trying to expand diverse techniques related to Biology and Pharmacology, to support various drug discovery purpose for different indications and clinical needs, we do have quite a lot of new assays development experience and passion, to accomplish target identification and assay validation, compounds screening from hit to lead, to pre-clinical drug candidate selection. | $14.2M / Series B / Aug 03, 2023 | |
| See all 23 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alwin Capital invest in?
Alwin Capital invests primarily in Medical, Biotechnology and Health Care startups, most often at Series A and Series B stage. Most of the 23 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Alwin Capital?
Public channels for Alwin Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Alwin Capital?
The team at Alwin Capital includes Lin Sibo (Executive Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
